Marketing-authorisation holder · United States
GlaxoSmithKline LLC
158 medicines in 1 country, as authorisation holder and manufacturer.
Loading…
Marketing-authorisation holder · United States
158 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 158
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTIDIL1.25mg/5ml · Syrup | Triprolidine | United States | Not marketed | |
| ACTIDIL2.5mg · Tablet | Triprolidine | United States | Not marketed | |
| ACTIFED120mg; 5mg · Capsule, extended release | Pseudoephedrine, Triprolidine | United States | Not marketed | |
| ACTIFED W/ CODEINE10MG/5ML; 30MG/5ML; 1.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Syrup | Codeine, Pseudoephedrine, Triprolidine | United States | Not marketed | |
| AEROSPORIN500,000 units base/vial · Injectable | Polymyxin b | United States | Not marketed | 1980 |
| AGENERASE15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Amprenavir | United States | Not marketed | 1999 |
| AGENERASE150mg | 50mg · Capsule | Amprenavir | United States | Not marketed | 1999 |
| AMERGE1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Naratriptan | United States | Not marketed | 1998 |
| AMOXIL125MG/5ML | 125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG/5ML | 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectivenes · For suspension | Amoxicillin | United States | Marketed | 1974 |
| AMOXIL250MG | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 500MG | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Amoxicillin | United States | Marketed | 1974 |
| ANCEF10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons · Injectable | Cefazolin | United States | Not marketed | 1973 |
| ANORO ELLIPTA0.0625mg base/inh; 0.025mg base/inh · Powder | Umeclidinium bromide, Vilanterol trifenatato | United States | Marketed | 2013 |
| ANSPOR125mg/5ml | 250mg/5ml · For suspension | Cephradine | United States | Not marketed | 1974 |
| ANSPOR250mg | 500mg · Capsule | Cephradine | United States | Not marketed | 1974 |
| ANTEPAR500mg base · Tablet | Piperazine | United States | Not marketed | 1957 |
| ANTEPAR500mg base/5ml · Syrup | Piperazine | United States | Not marketed | 1957 |
| ARNUITY ELLIPTA0.05mg/inh | 0.1mg/inh | 0.2mg/inh · Powder | Fluticasone | United States | Marketed | 2014 |
| BACTOCILL10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Oxacilina | United States | Not marketed | 1982 |
| BACTOCILL250mg base | 500mg base · Capsule | Oxacilina | United States | Not marketed | 1973 |
| BACTOCILL250mg base/5ml · For solution | Oxacilina | United States | Not marketed | 1981 |
| BACTROBAN2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Mupirocin | United States | Not marketed | 1995 |
| BACTROBAN2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Cream | Mupirocin | United States | Not marketed | 1997 |
| BACTROBAN2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Ointment | Mupirocin | United States | Not marketed | 1987 |
| BECLOVENT0.042mg/inh · Aerosol, metered | Beclometasone | United States | Not marketed | 1980 |
| BECONASE0.042mg/inh · Aerosol, metered | Beclometasone | United States | Not marketed | 1981 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 158 | 155 | 3 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep GlaxoSmithKline LLC’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.
Ranked by their number of medicines.